Escolar Documentos
Profissional Documentos
Cultura Documentos
Pharmacologic Name
Adalimumab
Pharmacologic Class
BIOLOGIC RESPONSE MODIFIER
Tumor necrosis factor (TNF) blocker.
Tumor necrosis factorsrefer to a group
ofcytokinesthat can cause cell death (apoptosis).
Cytokinesare a broad and loose category of small
proteins that are important incell signalling.
Formulations
soln for SC inj - prefilled syringe n prefilled pen
10mg/0.2mL,
20mg/0.4mL,
40mg/0.4mL,
40mg/0.8mL;
Indications
rheumatoid arthritis
juvenile idiopathic arthritis
psoriatic arthritis
ankylosing spondylitis
plaque psoriasis
hidradenitis suppurativa
Crohn's disease
ulcerative colitis
Mechanism of action
Psoriasis is a chronic, inflammatory disease/ immune
mediated disease.
The interaction of multiple immune cell types including
T-cells, macrophages, and dendritic cells induces
abnormally rapid keratinocytic proliferation and
incomplete maturation.
These abnormalities result in thickening and scaling of
the skin.
Increased levels of TNF are found in psoriasis plaques.
side effects
injection site reactions
hives;
difficulty breathing;
swelling of your face, lips, tongue, or throat.
Because adalimumab suppressesTNF, which is part of
the immune system, latent infections, such
astuberculosis, can be reactivated, and the immune
system may be unable to fight new infections